Overviewing Cardiac Safety Profile of Vildagliptin 100mg SR -ft-Prof. Dr Aravinda Jagadeesha

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-12-05 06:30 GMT | Update On 2023-05-03 07:28 GMT

Vildagliptin has established itself over the years by controlling the blood sugar levels in patients with type 2 diabetes mellitus. It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It also displays significant HbA1c lowering and has a low risk of edema, as well as that of hypoglycemia. These characteristic features make vildagliptin a favorable partner for combination therapy as well as newer formulations like sustained release.

In this video, Prof. Dr Aravinda Jagadeesha, a diabetologist and the chairman at Dr. Aravinds Diabetes Centre in Bengaluru, India talks about how Vildagliptin and how it has proven itself in the past 15 years. In particular, Dr Jagadeesha provides his viewpoints on the cardiac safety profile of Vildagliptin 100mg SR.

In the case of Cardiovascular Safety, Vildagliptin has a plethora of studies including 3 Real-world studies, 3 Meta-analyses, and 1 RCT, establishing safety in over 10 lakh patients. The studies demonstrated that Vildagliptin is not associated with increased Cardiovascular risk, including the risk of Chronic Heart Failure. Even a thorough QT study demonstrated that Vildagliptin has no prolonged QT interval or effect on cardiac conduction even at the highest daily therapeutic dose.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Overviewing Cardiac Safety Profile of Vildagliptin 100mg SR -ft-Prof. Dr Aravinda Jagadeesha

Similar News